Sedivention announced it secured €2.9 million in seed financing to continue development of its outpatient obesity treatment platform and generate initial clinical data ahead of market entry.
The financing round was led by bmp Ventures alongside the IBG funds, with participation from the strategic investment arm of a global medtech company, High-Tech Gründerfonds, superangels, and Cambridge Ventures.
Sedivention develops minimally invasive obesity therapies designed to address hunger and satiety regulation without surgery, implants, or lifelong medication use. The company said current obesity treatment options remain limited due to invasiveness, accessibility constraints, and long-term medication requirements.
The company’s approach is based on a targeted cryo procedure using a proprietary cryo balloon catheter inserted similarly to a gastroscopy. According to Sedivention, the system uses precise cryoablation to interrupt hunger-related gastric branches of the vagus nerve, targeting physiological drivers associated with obesity.
Sedivention said the therapy is designed as a one-time outpatient interventional procedure that leaves no foreign material in the body and is intended to provide long-term reduction in hunger sensations.
The company noted that a functional prototype has already been developed and tested. The new financing will support completion of product development, execution of a First-in-Human clinical study, and preparation for future regulatory and clinical milestones.
Sedivention said its long-term objective is to replace highly invasive bariatric surgical procedures with scalable outpatient interventions capable of expanding access to obesity treatment globally.
The company operates from Magdeburg and Munich and focuses on development of minimally invasive medtech therapies for obesity treatment.
KEY QUOTES:
“Obesity is a chronic condition that requires treatments that are medically effective yet gentle. Our approach directly addresses the underlying disruption in hunger and satiety regulation, enabling a lasting reduction in feelings of hunger – without surgery, without implants, and without lifelong medication.”
Dr. med. Ute Nollert, Founder And Chief Medical Officer, Sedivention
“We are developing a proprietary medtech solution with the potential to redefine a global market worth billions through scalable, outpatient treatment. Our technology has been designed for international scalability from the outset and addresses a market that has not yet been efficiently tapped, with significant growth potential.”
Dr. Andreas Bröcker, Co-Founder And CEO, Sedivention
“Sedivention combines medical evidence with a clearly scalable and cost-effective medtech approach. The team is addressing a globally relevant medical condition with a technologically compelling solution.”
Dr. Jan Engels, Senior Investment Manager, HTGF
“Sedivention is developing an innovative and compelling MedTech technology to sustainably redefine obesity therapy. The solution has enormous transformative potential for one of the world’s largest healthcare markets.”
Carlos Figueredo, Investment Manager, bmp Ventures
“When we look back in 10 years, Sedivention will be one of the companies that changed obesity treatment forever. Existing solutions manage – Sedivention solves. That’s the kind of impact we look for: a team with the conviction and the technology to redefine one of the largest markets in the world.”
Franzi Majer, Founding Partner, superangels
